Why Edibles Hit Different
The pharmacology behind why a 10 mg gummy can feel stronger, longer, and weirder than a 10 mg joint.
Edibles aren't 'stronger' because of magic — they're stronger because your liver turns THC into 11-hydroxy-THC, a metabolite that crosses into the brain efficiently and lasts for hours. Onset is slow (30 min to 2 hr), peak is delayed, and the dose-response curve is steep. Most 'I greened out' stories are people redosing during that lag. The chemistry is real; the dosing advice is boring but correct: start low, wait long, don't stack.
Not medical advice
This article summarizes published pharmacology and clinical data on oral cannabis. It is not medical advice, not a dosing recommendation, and not a substitute for talking to a clinician — especially if you take other medications, are pregnant, have a cardiac or psychiatric history, or are considering cannabis for a medical condition. Laws vary by jurisdiction.
Plain-language summary
When you smoke or vape THC, it goes lungs → blood → brain in minutes. When you eat THC, it goes gut → liver → blood → brain over the course of an hour or two. That detour through the liver matters: a large fraction of the THC gets converted to 11-hydroxy-THC (11-OH-THC), which is itself psychoactive and crosses the blood-brain barrier well [1][2] Strong evidence.
The practical consequences:
- Slow onset (typically 30–120 minutes) [3] Strong evidence.
- Delayed peak (2–4 hours) and long tail (often 6–8 hours, sometimes longer) [3][4] Strong evidence.
- Highly variable bioavailability between people and between meals [1][2] Strong evidence.
- Easy to overshoot by redosing before the first dose has kicked in [5] Strong evidence.
The popular claim that edibles are 'four times stronger mg-for-mg' is folklore. The truth is messier: they're slower, longer, more variable, and often feel qualitatively different — but the size of that 11-OH-THC effect in humans is still debated Disputed.
What probably works (strong evidence)
1. Oral THC has delayed onset and prolonged duration vs. inhaled. Controlled pharmacokinetic studies repeatedly show plasma THC peaks within ~10 minutes after smoking but 1–3 hours after oral dosing [1][2][3] Strong evidence.
2. First-pass hepatic metabolism produces large amounts of 11-OH-THC. After oral dosing, 11-OH-THC plasma concentrations are typically comparable to or higher than THC concentrations; after smoking, they are much lower [1][2] Strong evidence.
3. 11-OH-THC is psychoactive. Direct IV administration of 11-OH-THC in humans produces cannabis-like subjective effects [6] Strong evidence.
4. Overconsumption of edibles drives emergency department visits. Colorado data showed a disproportionate share of cannabis-related ED visits came from edibles relative to their market share, often involving accidental overdose, anxiety, and cardiovascular symptoms [5] Strong evidence.
5. Start-low-go-slow reduces adverse events. This is the consensus harm-reduction recommendation from public health agencies in legal markets [7] Strong evidence.
What might work (weak or mixed evidence)
11-OH-THC is 'stronger' than THC. The often-repeated claim that 11-OH-THC is 1.5–4× more potent than THC traces to older animal and limited human work [6] Weak / limited. It probably is somewhat more potent at CB1 receptors and crosses the blood-brain barrier well, but the precise human potency ratio at realistic edible doses is not well established Disputed.
Eating fat with your edible increases absorption. A small human study found a high-fat meal increased CBD exposure roughly 4-fold [8] Weak / limited. Analogous data for THC edibles in humans are thinner. The 'take it with butter' advice is plausible pharmacology but not strongly validated for finished products.
Sublingual / buccal absorption bypasses first-pass metabolism. True if the product is genuinely held under the tongue, but most 'sublingual' tinctures get swallowed and behave like edibles [9] Weak / limited.
Tolerance to edibles develops similarly to inhaled cannabis. Likely true based on CB1 downregulation studies, but head-to-head comparisons across routes are sparse Weak / limited.
What doesn't work / folklore
- '10 mg is 10 mg.' No. Bioavailability of oral THC ranges roughly 4–20% across individuals and conditions [1][2] Strong evidence. Same gummy, different person, very different blood levels.
- 'Indica edibles will couch-lock you, sativa edibles will energize you.' The indica/sativa label does not reliably predict effects, and after first-pass metabolism the chemotype differences are even further muddied. See Indica vs Sativa: The Myth Disputed.
- 'If you don't feel it in an hour, take more.' This is the single most common path to a bad time. Peak isn't for 2–4 hours [3] Strong evidence.
- 'Edibles don't show up on drug tests.' They absolutely do — often for longer, because of prolonged 11-OH-THC and THC-COOH excretion Strong evidence.
What we don't know
- The precise in vivo potency of 11-OH-THC vs. THC in humans at edible-relevant doses.
- How much inter-individual variability is genetic (e.g., CYP2C9, CYP3A4 variants) vs. meal composition vs. gut transit Weak / limited.
- Whether minor cannabinoids and terpenes survive cooking and first-pass metabolism in pharmacologically relevant amounts. Most 'entourage' claims are extrapolations from in vitro work Weak / limited.
- Long-term effects of frequent high-dose edible use specifically, separated from smoked cannabis.
Comparison with standard treatments and other routes
For approved medical indications, two oral cannabinoid products have substantial clinical-trial data:
- Dronabinol (synthetic THC, oral) — FDA-approved for chemotherapy-induced nausea and AIDS-related anorexia. Same first-pass pharmacology as edibles: slow onset, high 11-OH-THC, long duration [10] Strong evidence.
- Nabiximols (Sativex, oromucosal THC:CBD spray) — designed partly to avoid first-pass metabolism, with faster and more predictable onset than swallowed products [11] Strong evidence.
Vs. inhaled cannabis: faster onset, easier self-titration, shorter duration, lower 11-OH-THC exposure — but with respiratory risks and (for combustion) tar and CO exposure.
Vs. standard pharmacotherapy (e.g., ondansetron for nausea, zolpidem for sleep, gabapentin for neuropathic pain): standard treatments generally have stronger and more specific evidence bases. Edibles may be useful adjuncts in some patients but should not be assumed equivalent to first-line treatments Weak / limited.
Risks
- Acute overconsumption: anxiety, panic, tachycardia, vomiting, dissociation, and rarely transient psychotic symptoms. Driven by the onset–peak lag and redosing [5] Strong evidence.
- Pediatric exposures: edibles that look like candy are a documented poisoning hazard; cases have risen sharply in legal markets [12] Strong evidence.
- Cardiovascular events: case reports and population data link acute high-dose THC to MI and arrhythmia in susceptible patients Weak / limited.
- Drug interactions: CBD and to a lesser extent THC inhibit several CYP450 enzymes; relevant for warfarin, clobazam, tacrolimus, and others Strong evidence.
- Cannabinoid hyperemesis syndrome with chronic heavy use, regardless of route Strong evidence.
- Driving impairment lasts longer with edibles than with inhaled cannabis Strong evidence.
If you are using edibles medically, talk to a clinician who knows your full medication list. See also Dosing Cannabis Edibles Safely and Greening Out: What To Do.
Sources
- Peer-reviewed Huestis MA. Human cannabinoid pharmacokinetics. Chemistry & Biodiversity. 2007;4(8):1770-1804.
- Peer-reviewed Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics. 2003;42(4):327-360.
- Peer-reviewed Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users. Clinical Chemistry. 2016;62(12):1579-1592.
- Peer-reviewed Vandrey R, Herrmann ES, Mitchell JM, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. Journal of Analytical Toxicology. 2017;41(2):83-99.
- Peer-reviewed Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Annals of Internal Medicine. 2019;170(8):531-537.
- Peer-reviewed Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. 1972;177(4043):62-64.
- Government Colorado Department of Public Health and Environment. Marijuana Health Information & Public Education: Edibles and Dosing Guidance.
- Peer-reviewed Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586-1592.
- Peer-reviewed Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta-9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clinical Chemistry. 2011;57(1):66-75.
- Government U.S. Food and Drug Administration. Marinol (dronabinol) capsules — prescribing information.
- Peer-reviewed Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management. 2008;4(1):245-259.
- Peer-reviewed Tweet MS, Nemanich A, Wahl M. Pediatric edible cannabis exposures and acute toxicity: 2017–2021. Pediatrics. 2023;151(2):e2022057761.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.